REG - Diaceutics PLC - Directorate Change

DiaceuticsAnnouncement

11/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220111:nRSK9933Xa&default-theme=true

RNS Number : 9933X  Diaceutics PLC  11 January 2022

11 January 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Directorate Change

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is
pleased to announce the appointment of Nick Roberts as Chief Financial Officer
and director of the Board, effective as of mid-March 2022. At the same time,
current Chief Financial Officer Philip White will step down from his role and
the Board to pursue new business opportunities. Philip will remain with the
business until the end of April to provide for an orderly handover of duties.

Nick is a highly experienced senior finance professional with a track record
of managing and developing finance functions and governance structures in high
growth AIM-listed healthcare and technology companies with global customer
bases.

He is currently Head of Group Reporting at AIM-quoted Ergomed plc, a
full-service pharmacovigilance and specialist clinical trial service provider
to the pharmaceutical and biotechnology industries with over 1,250 employees
and a market capitalisation of c.£640m. During his tenure, Nick has developed
and managed the day-to-day group finance reporting requirements for Ergomed
plc and has overseen the roll-out of several governance framework and
reporting projects, including the financial integration of two US business
acquisitions. Prior to this, Nick was Group Financial Controller at AIM-quoted
Ceres Power Holdings plc, a fuel cell and electrochemical technology
development company, leading the development of the finance function to
accommodate a period of considerable commercial and financial growth over four
years.

Nick is a Fellow Chartered Accountant with the Institute of Chartered
Accountants in England and Wales (ICAEW) and holds a bachelor's degree in
Accounting and Finance from the University of Southampton.

Peter Keeling, CEO and Founder of Diaceutics PLC, commented:

"I am delighted to welcome Nick to Diaceutics. Nick's background working with
high-growth, platform-oriented businesses across tech and pharma makes him an
excellent fit, and his experience leading finance functions to accommodate
significant year-on-year revenue growth will serve as a real asset to us. I
look forward to welcoming Nick to the team as we look to take Diaceutics to
its next level of growth and accelerate the transformation of our business
model.

"Equally, I would like to wholeheartedly thank Philip for his contribution to
Diaceutics, having led us through a successful IPO and played a key role in
the first few years as a public company. We wish him all the best in his
future business."

Information required to be disclosed pursuant to Schedule Two, paragraph (g)
of the AIM Rules for Companies:

Nicholas Stewart Roberts, aged 39, has no current or previous directorships or
partnerships within the past five years.

Save for the information disclosed above, there is no other information to be
disclosed under Schedule 2(g) of the AIM Rules.

Nick Roberts does not hold any ordinary shares in the Company.

 

Enquiries:

 Diaceutics PLC
 Peter Keeling, Chief Executive Officer               Via Alma PR

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison, Stewart Wallace, Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde, Kieran Breheny, Matthew Young        diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABKKBQFBKDCDD